BBIO Stock Forecast & Price Target

BridgeBio Pharma is demonstrating robust financial momentum, with revised full-year 2026 revenue forecasts indicating growth from $763.4 million to $766.3 million, bolstered by increasing sales projections for its key product, Attruby (acoramidis). The company is showing strong traction in the market, having recorded over 5,259 unique patient prescriptions since its launch, reflecting a solid increase in uptake among treatment-naïve patients, which positions it favorably to potentially lead in the ATTR-CM space. Additionally, the positive clinical outcomes for BBP-418 and encaleret enhance the company’s pipeline prospects, setting the stage for significant revenue generation and potential accelerated regulatory approvals that could further drive its market position.

BridgeBio Pharma faces a daunting financial outlook, primarily highlighted by a projected full-year 2025 net loss of $3.59 billion, alongside a recent quarterly net loss of $182.7 million that exceeded consensus expectations. The company is burdened by limited cash reserves and substantial debt, raising concerns about its ability to sustain operations in the event of clinical or commercial setbacks, especially given the potential competitive pressures from generics like tafamidis. Additionally, risks associated with its pipeline assets, including possible failures to demonstrate safety and efficacy, exacerbate the uncertainty surrounding the company's future revenue generation and market penetration capabilities.